Drug
Alemtuzumab GZ402673
Alemtuzumab GZ402673 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
1
20%
Ph phase_4
2
40%
Ph phase_3
1
20%
Phase Distribution
1
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
terminatedphase_3
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
NCT03368664
terminated
LEMTRADA Pregnancy Registry in Multiple Sclerosis
NCT03774914
completedphase_4
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
NCT02255656
completedphase_1
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
NCT02583594
completedphase_4
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
NCT02205489
Clinical Trials (5)
Showing 5 of 5 trials
NCT03368664Phase 3
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
NCT03774914
LEMTRADA Pregnancy Registry in Multiple Sclerosis
NCT02255656Phase 4
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
NCT02583594Phase 1
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
NCT02205489Phase 4
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5